Alzheimer's disease has resisted single-target drug treatments because it's not one problem but a tangled web of biological factors working together. Scientists are now shifting away from treating Alzheimer's as a straightforward protein-buildup disease toward comprehensive, multi-pronged strategies that address genetics, aging, brain inflammation, and whole-body health simultaneously .

Why Have Alzheimer's Drugs Fallen Short Despite Recent Breakthroughs?

Recent medications like lecanemab and donanemab, which are monoclonal antibodies designed to clear amyloid-beta protein from the brain, have offered some hope by slowing cognitive decline. However, these treatments still cannot reverse the disease or restore normal brain function . The reason, according to a comprehensive review published in Science China Life Sciences, is that researchers have been fighting Alzheimer's with one hand tied behind their backs.

Professor Yan-Jiang Wang and colleagues argue that focusing exclusively on amyloid-beta has not worked because Alzheimer's arises from the combined effects of multiple interconnected factors. The disease involves amyloid-beta buildup, tau protein tangles, genetic risk factors, aging-related changes, and broader health conditions all working together to damage the brain . Treating only one piece of this puzzle leaves the others untouched.

What Are the Multiple Biological Factors Driving Alzheimer's?

Understanding Alzheimer's complexity requires looking beyond the two proteins that have dominated research for decades. Scientists have identified several key areas that reshape how the disease develops and progresses:

• Tau Protein Spread: While amyloid-beta has been the focus, tau protein tangles may be equally important. Tau begins sticking together inside brain cells, forming neurofibrillary tangles that impair neural function and eventually kill cells. New research shows tau spreads from one brain region to another through connected neurons, following each person's unique brain wiring patterns .
• Genetic Risk Factors: Beyond the well-known APOE epsilon-4 gene, researchers are identifying additional genetic variants linked to Alzheimer's risk in specific populations. Advances in genome editing technology like CRISPR/Cas9 are being explored as potential one-time treatments that could modify disease risk at its source .
• Aging and Cellular Damage: Aging is the strongest risk factor for Alzheimer's and involves declining mitochondrial function, buildup of damaged cells, and increased DNA damage. Senolytic therapies, which aim to remove aging glial cells, are being investigated as a way to improve brain health and slow cognitive decline .
• Systemic Health Conditions: Insulin resistance, high blood pressure, and imbalances in gut bacteria can worsen Alzheimer's disease processes. Researchers are investigating whether existing diabetes medications and therapies targeting the gut-brain axis could help reduce these effects .

A decade-long study of 128 participants, averaging 91 years old at death, provided crucial insights into how tau spreads. Researchers from the University of Alabama at Birmingham, Rush University Medical Center, and SUNY Upstate Medical Center examined brain samples and brain imaging data to understand tau's movement through the brain . Nearly one-third of the study participants had Alzheimer's dementia, providing a robust sample for analysis.

"Small pieces of tau make up the aggregate inside the neuron and spread from neuron to neuron through the brain. Neurons are connected to each other, and they talk to each other through synapses. This would allow them to get around the brain and deposit and aggregate at different brain sections until they reach the neocortex," said Jeremy Herskowitz, Professor of Neurology and Neurobiology at UAB.

Jeremy Herskowitz, Ph.D., Professor of Neurology and Neurobiology at University of Alabama at Birmingham

The research revealed that tau seeds spread primarily along an individual's natural communication pathways. Each person's unique brain connectivity helps determine how far and how fast tau pathology advances . This finding explains why Alzheimer's progression varies so dramatically from person to person.

How Can Doctors Move Toward Multi-Target Alzheimer's Treatment?

• Precision Medicine Approaches: Using early biomarkers like plasma pTau217 (a form of tau protein detectable in blood), doctors can identify and treat Alzheimer's earlier and more accurately in individual patients .
• Advanced Laboratory Models: Researchers are using human iPSC-derived organoids, which are miniature brain-like structures grown in the lab, to test new therapies more effectively before moving to human trials .
• Tau-Targeting Antibodies: Previous clinical trials have shown that tau traveling outside of cells is susceptible to therapeutic antibodies. By stopping tau from spreading from one brain region to the next, these treatments could delay or prevent Alzheimer's dementia .
• Combination Drug Strategies: Rather than relying on a single medication, future treatments will likely combine therapies targeting amyloid, tau, genetic factors, aging processes, and systemic health conditions simultaneously .

"Success in defeating Alzheimer's hinges on interdisciplinary collaboration and holistic innovation. With the right combination of strategies, Alzheimer's could eventually become a manageable or even preventable condition rather than an inevitable decline," the researchers concluded.

Professor Yan-Jiang Wang and colleagues, Science China Life Sciences

The shift toward multi-target approaches represents a fundamental change in how scientists think about Alzheimer's. Rather than viewing it as a single disease caused by one faulty protein, researchers now understand it as a complex system where multiple biological processes interact and amplify each other's damage. This perspective opens new therapeutic possibilities that single-drug approaches could never achieve .

The implications are significant for the millions of people living with Alzheimer's and their families. While no cure exists yet, the emerging understanding that Alzheimer's can be attacked from multiple angles simultaneously offers genuine hope that future treatments could slow, halt, or even prevent cognitive decline more effectively than current medications alone.